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Introduction
The incidence of bladder cancer continues to 
increase. In the US, around 45,000 men and 17,000 
women were diagnosed with bladder cancer each 
year [1]. In 2009, Ploeg et al. showed that more than 
2.7 million people had a history of bladder cancer 
and more than 12 million new cases occurred in the 
world in 2003. A total of 5.4 million cases occurred in 
developed countries and 6.7 million cases occurred 
in developing countries [2], [3]. The incidence of 
bladder cancer is ranked ninth in the world of all types 
of cancer [2]. An estimated 386,300 bladder cancers 
are new cases and around 150,200 bladder cancer 
died in the world in 2008 [4]. Bladder cancer is more 
common in men than women, with overall a ratio of 
3:1, but ratio could reach 5:1 in certain country. In 
Iran, 83% bladder cancer occurs in male [5]. Five-
year survival rate of bladder cancer was around 
77.3% [6].
The most common type of bladder cancer 
occurs in cells lining called transitional cell carcinoma or 
urothelial carcinoma. In general, the type of transitional 
cell carcinoma is not invasive. Another type of bladder 
cancer is squamous cell (carcinoma originating from 
thin, flat cells due to inflammation or irritation for 
months or even years) and adenocarcinoma from the 
gland. In the US, more than 90% of cancer bladder is 
a type of transitional cell carcinoma. The remaining 
3–8% are squamous cell carcinomas and 1% are 
adenocarcinoma types. Other types such as sarcoma 
and small cell carcinoma can also occur, but are very 
rare [7], [8].
Bladder cancer is also classified based on the 
invasion of the muscularis propria in the bladder wall. 
Studies show that 75–80% of cases are non-muscle 
invasive bladder cancer (NMIBC) which consists of 
Stage Ta (papillary), T1 (invading into the lamina 
propria), and carcinoma in situ [9]. Meanwhile, MIBC is 
a more severe condition. Patients with NMIBC generally 
can be managed with intravesical chemotherapy 
or immunotherapy and neoadjuvant chemotherapy 
followed by radical cystectomy with bilateral pelvic 
lymph node dissection which is a standard of care for 
MIBC patients [10].
Bladder cancer can cause hematuria, dysuria, 
frequent urination, and feeling the need to urinate but 
not being able to pass urine. Symptoms of bladder 
cancer are often not specific. Cystitis can also occur. 
The etiology of bladder cancer is not fully known. 
The main risk factors for cancer bladder are smoking; 
exposure to chemicals and drugs such as phenacetin, 
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cyclophosphamide, and chlornaphazine; bladder 
inflammation due to infections of microbes and parasites 
such as schistosomiasis; and genetics. Genetic factors 
such as mutation or polymorphism in various genes have 
been widely studied [1], [11]. Although many people 
are exposed to these risk factors, only a few people 
experience bladder cancer. This indicates the presence 
of genetic factors that cause variations in susceptibility 
to bladder carcinogenesis. Several studies found that 
gene polymorphism is associated with an increased 
risk of developing cancer, both independently and in 
combination with other carcinogenic factors. Identifying 
gene polymorphisms can help predict a person’s risk of 
cancer, one of them is vascular endothelial growth factor 
(VEGF) gene polymorphism [12], [13].This literature 
evaluates VEGF expression and VEGF polymorphism 
in bladder cancer.
Methods
This review included in vitro and in vivo studies 
that discuss role of VEGF and VEGF polymorphism on 
bladder cancer. Level or expression of VEGF could be 
determined by either blood test, immunohistochemistry, 
or mRNA level while VEGF polymorphism was 
determined by polymerase chain reaction-restriction 
fragment length polymorphism technique or other 
molecular techniques. Only VEGF-A (also known as 
VEGF) publication was included. Therefore, publications 
that only examine VEGF-B, VEGF-C, and VEGF-D 
without mentioning VEGF-A were excluded from the 
study. We also excluded review article, systematic 
review, and meta-analysis.
We searched PubMed for suitable papers 
published from January 1, 1999, to January 1, 
2019 (20 years). Keywords used were VEGF, 
polymorphism, bladder cancer, and their synonym. 
A total 15 publications were reviewed. Role of VEGF on 
bladder cancer was first reviewed; then, polymorphism 
of VEGF on bladder cancer risk was discussed. Method 
of literature searching can be seen in Figure 1.
VEGF expression in bladder cancer
Angiogenesis is a fundamental process 
of tumor growth, invasion, and metastasis. The 
angiogenesis process consists of multiple steps which 
are controlled by endothelial cells that get an angiogenic 
stimulus. This endothelial cell migration is accompanied 
by proliferation and formation of structures that can 
invade perivascular. Endothelial cell production 
does not only originate from the division of existing 
differentiated endothelial cells but also from the influx of 
bone marrow-derived circulating endothelial progenitor 
cells [14]. Angiogenesis can occur with sprouting 
(branching of new capillaries from existing vessels) 
and non-sprouting processes (cell multiplication within 
vessel walls) [15]. VEGF is the most potent regulator 
of angiogenesis [16]. VEGF specifically binds to VEGF 
receptor tyrosine kinase in endothelial cells to initiate 
the pathway of intracellular signal transduction that 
mediates angiogenesis and vascular permeability [13]. 
The VEGF function is not only for angiogenesis but 
also increases vascular permeability, induces leukocyte 
adhesion to the endothelium, and increases chemotaxis 
of monocyte [17]. In addition, VEGF can also activate 
NF-ĸβ and induce the synthesis of various pro-
inflammatory cytokines and chemokines [18].
There is an increase of VEGF expression 
and serum VEGF level in bladder cancer. Compare 
to healthy individual, patient with bladder cancer has 
higher serum VEGF level [19]. Expression of VEGF 
was also higher in bladder cancer specimens than in 
normal mucosa [20], [21]. Moreover, this higher level of 
VEGF can also be detected in urine of bladder cancer 
patient [22]. VEGF signaling is mediated through 
binding with VEGFR1 and VEGFR2 receptors [23], [24]. 
Similar to VEGF, increased VEGFR expression is also 
found in bladder cancer specimen [20], [21]. Therefore, 
this marker could be used as diagnostic biomarker for 
patients with bladder cancer [25]. Elevation of both 
proteins is associated with tumor progression, lymph 
node or distant metastasis, survival, and recurrence.
VEGF is correlated with both pathologic 
and histologic state in bladder cancer. Higher VEGF 
expression tends to have higher T grade (in TMN 
staging) and higher histologic of bladder cancer [20]. 
Its serum level is also higher in MIBC than NMIBC 
and normal patient [19]. Moreover, its overexpression 
is also associated with lymphovascular invasion and 
lymph node metastasis [26], [27]. However, other 
studies also showed the opposite that serum VEGF 
and its expression were higher in superficial, well-
differentiated bladder cancer compared to the invasive, 
poorly differentiated bladder cancer [21], [28]. This 
could indicate that elevation of VEGF expression 
starts since the development of primary tumor. Its level 
increases until it reaches certain point at advance 
bladder cancer. After that, there is a reduction in 
vascular destabilization and decreased formation 
of new blood vessels, suggesting balance between 
Potentially relevant
studies (n=434)
Excluded because of article type
and irrelevant title (n=397)
Relevant title. Abstract
reviewed (n=37)
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Figure 1: Method of literature searching
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vessel regression and vascular growth [29]. VEGF 
is potential prognostic marker in bladder cancer. 
Excessive expression of VEGF in tumors is associated 
with poor prognosis [24], [30]. Furthermore, it is 
associated with disease-free survival [27]. Patient with 
overexpression of VEGF has shorter survival without 
progression [20], [31]. It is also suggested that serum 
VEGF level could be used as predictor of overall and 
cancer death and to define high-risk individual that may 
benefit from prevention therapy [32].
Given the important role of VEGF in bladder 
cancer pathogenesis, antiangiogenic therapy targeting 
VEGF and its receptor is developed. Its role continues to 
be investigated as adjuvant and neoadjuvant therapies 
for bladder cancer [33], [34], [35].
Role of VEGF polymorphism for bladder 
cancer risk
Genetic factors continue to be studied for the 
incidence of bladder cancer. Genetic polymorphism 
contributes to the risk of developing bladder cancer. 
Various studies have shown genetic polymorphisms 
to affect vulnerability and clinicopathological 
characteristics of bladder cancer, one of them is VEGF 
gene polymorphism [13], [36]. The VEGF gene is located 
on chromosome 6p21.3 and consists of 8 exons and 7 
introns. More than 30 single-nucleotide polymorphisms 
(SNPs) of VEGF have been described. The range of 
encoding genes is approximately 14 kb [13].
Several SNPs have been identified in the 
VEGF gene. These VEGF SNP positions are shown in 
Figure 2.
of DNA that facilitates gene transcription. The base pair 
sequence of the promoter determines the efficiency of 
binding with RNA polymerase and thus determines the 
transcription efficiency. In addition, SNPs located in the 
5’ untranslated region (UTR) and 3’ UTR can also affect 
VEGF levels. 5’UTR is a regulator DNA region where 
the genes coding for the protein will be transcribed 
into mRNA. Polymorphism involving allele changes in 
5’UTR of VEGF gene will cause the appearance of SP-1 
(CCACC box) which is a transcription factor. The variation 
of alleles on 5’UTR can cause an increase in transcription 
factors. Variation of alleles on 3’-UTR of the VEGF 
gene can affect the stability of mRNA and is associated 
with the hypoxic induction of VEGF. Human antigen R 
(HuR) proteins are considered to play a role in mRNA 
stabilization and prevent mRNA from being attacked by 
RNAse. HuR proteins also increase the binding of VEGF 
mRNA to the nucleus and increase the export of VEGF 
mRNA in hypoxic-induced angiogenesis [39], [40].
Renner et al., in Austria (2000), examined the 
relationship of VEGF +936C>T polymorphism in the 
3-UTR of the VEGF gene with VEGF plasma levels 
in 23 healthy individuals. VEGF plasma levels were 
significantly lower in carriers of the 936T allele than in 
non-carriers [41]. Krippl et al.’s study in Austria (2003) 
of 500 breast cancer patients and 500 healthy controls 
showed that subjects with the T allele of VEGF +936C>T 
polymorphism had significantly lower VEGF plasma 
levels and it was proved that individuals with T allele 
were protective against breast cancer [42]. A study 
by Koukourakis on lung cancer patients in Greece 
reported that the −2578CC, −634GG, −1154AA, and GA 
genotypes in the VEGF gene were associated with low 
VEGF expression, while the −2578CA, −634 GC, and 
−1154GG genotypes were associated with high VEGF 
expression [43]. Research by Awata et al. (2002) in Japan 
showed that VEGF serum levels increased significantly 
in 118 healthy individuals with −634 CC genotypes 
compared with GC and GG genotypes. Meanwhile, 
VEGF +936C>T and +1612G>A polymorphisms were 
not associated with VEGF levels [44]. 
Yang et al. reported that AA genotype of 
VEGF −15,648A>C significantly increased the risk of 
1.75 times experiencing bladder cancer in Chinese 
ethnic [45]. A study by Garcia-Closas et al., in Spain, also 
found that individuals who had AA genotype of VEGF 
−15,648A>C polymorphism significantly increased 
the risk of 2.52 times having bladder cancer [46]. This 
result is similar to the research conducted by Fu et al., 
in China, that AC genotype (odds ratio [OR] = 1.49; 95% 
confidence interval [CI] = 1.25–1.87; p ≤ 0.001), AA 
genotype (OR = 2.1; 95% CI = 1.41–2.86; p ≤ 0.001], 
and CA + AA genotypes (OR = 1.65; 95% CI = 1.23–
2.12; p ≤ 0.001] of VEGF −15,648 A>C polymorphism 
associated with an increased risk of bladder cancer [47].
Garcia-Closas et al. found that individuals 
who had TT genotype of VEGF −7C>T polymorphism 
increased the risk of 5.11 times getting bladder cancer. 
Figure 2: Vascular endothelial growth factor (VEGF) gene structure 
and VEGF single-nucleotide polymorphisms positions [37]
Some SNPs in the VEGF gene can affect the 
expression of these genes. Certain allele variations can 
result in an increase in transcription factors that will bind to 
the promoter site, this site is the initial site of attachment of 
the RNA polymerase enzyme that is useful for transcription 
process. Transcription factors are proteins that control the 
rate of transcription of genetic information. Transcription 
factors both alone and together with other proteins 
in a complex can be as activators of RNA polymerase 
recruitment, stabilization of RNA polymerase bonds, and 
catalyzing histone acetyltransferase activity which can 
increase the rate of transcription so that plasma proteins 
can increase which can cause a disease or accelerate 
the progression of the disease [38]. Promoter is a part 
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Meanwhile, Jaiswal et al., in India, and Fu et al., in China, 
showed that the VEGF −7C>T polymorphism was not 
associated with the risk of bladder cancer [46], [47], [48].
The study by Longo et al., in Italy, of 46 
bladder cancer patients and 100 controls found that 
the combination of TT and CT genotypes in the VEGF 
+936C>T polymorphism increased the risk of 2.16 times 
for bladder cancer [49]. However, the results of research 
conducted by Longo et al. different from the results of 
research conducted by Yang et al., in China, Garcia-
Closas et al., in Spain, and Wafi et al., Tunisia, where 
they found that the VEGF +936C>T polymorphism 
had no significant association with an increased risk of 
bladder cancer [45], [46], [50].
Several studies were also conducted to 
evaluate the relationship between the polymorphism of 
VEGF −2578C>A and the incidence of bladder cancer. 
In a study conducted by Fu, in China, it was found 
that there was a relationship between CA genotype 
(OR = 1.33; 95% CI: 1.05–1.71; p = 0.012), AA genotype 
(OR = 2.35; 95% CI = 1.57–3.16; p ≤ 0.001), and CA + 
AA genotype (OR = 1.70; 95% CI: 1.16–2.31; p ≤ 0.001) 
of VEGF −2578C>A polymorphism with an increased 
risk of bladder cancer. This is also in line with Jaiswal’s 
research that there was a significant association between 
CA genotype of VEGF −2578C>A polymorphism 
(OR = 1.69; 95% CI = 1.02–2.80; p = 0.044) and an 
increased risk of bladder cancer [37], [38]. In contrast 
to those data, Wafi et al. found a significant reduction 
in risk for bladder cancer in subjects with CA genotype 
(OR = 0.62; 95% CI = 0.41–0.94, p = 0.026) and AA 
genotype (OR = 0.40, 95% CI = 0.21–0.76, p = 0.005) 
of VEGF −2578C>A polymorphism [50]. Meanwhile, 
the research conducted by Henríquez-Hernández et al. 
showed that VEGF −2578C>A polymorphism was not 
associated with the incidence of bladder cancer [51]. 
Other VEGF polymorphisms such as TT genotype of 
VEGF −9228G>T and TT genotype of VEGF −8339A>T 
were associated with an increased risk of bladder 
cancer, but CT genotype of VEGF +1378C>T was 
associated with a reduced risk of bladder cancer [46]. 
There was no association between VEGF −1498C>T 
and −634G>C polymorphisms with the risk of bladder 
cancer [47], [49]. The previous studies indicated 
potential associations between VEGF polymorphism 
and risk of bladder cancer; however, the results were 
inconclusive. Various studies that examined association 
between VEGF polymorphism and cancer risk showed 
different results due to ethnicity and geographical 
factors differences between studies [52].
Conclusion
Angiogenesis is a fundamental process of 
tumor growth, invasion, and metastasis. VEGF is a 
potent regulator of angiogenesis. There is an increase 
of VEGF expression in bladder cancer that associated 
with tumor progression, metastasis, recurrence, and 
survival. VEGF gene is a highly polymorphic and VEGF 
gene polymorphism that has been shown to affect the 
expression of VEGF proteins, which can affect the risk 
of cancer, tumor growth, and progression. The previous 
studies indicated potential associations between 
VEGF polymorphism and risk of bladder cancer. VEGF 
polymorphism might be an important risk factor for the 
initiation and progression of bladder cancer. The result 
of the previous studies showed inconsistent results 
due to differences in ethnicity and geographical factors 
between studies so that research needs to be done on 
each ethnic group.
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